Insmed, Inc. (INSM)
Stock Price:
$36.89 USD
-0.10 (-0.27%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
3.74B |
| Revenue (ttm) |
163.95M |
| Net Income (ttm) |
-241.89M |
| Shares Out |
101.48M |
| EPS (ttm) |
-2.65 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$36.89 |
| Previous Close |
$36.99 |
| Change ($) |
-0.10 |
| Change (%) |
-0.27% |
| Day's Open |
36.29 |
| Day's Range |
35.88 - 37.20 |
| Day's Volume |
618,729 |
| 52-Week Range |
12.09 - 39.39 |
More Stats
| Market Cap |
3.74B |
| Enterprise Value |
3.50B |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
101.48M |
| Float |
98.52M |
| EPS (basic) |
-2.64 |
| EPS (diluted) |
-2.65 |
| FCF / Share |
-2.31 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
11.28M |
| Short Ratio |
11.62 |
| Short % of Float |
11.45% |
| Beta |
2.49 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
22.83 |
| PB Ratio |
9.36 |
| Revenue |
163.95M |
| Operating Income |
-218.04M |
| Net Income |
-241.89M |
| Free Cash Flow |
-222.85M |
| Net Cash |
243.15M |
| Net Cash / Share |
2.40 |
| Gross Margin |
68.47% |
| Operating Margin |
-132.99% |
| Profit Margin |
-147.50% |
| FCF Margin |
-135.93% |
| ROA |
-16.15% |
| ROE |
-63.50% |
| ROIC |
-42.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$45.50*
(23.34% upside)
Low
35.0
Current: $36.89
High
56.0
Target: 45.50
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 136 | 9.84 | - | - | - | - | 11.50 | - | 4.42 | 6.92 |
| Revenue Growth | 1287.56% | - | - | - | - | - | - | - | -36.18% | - |
| Gross Profit | 112 | 7.41 | - | - | - | - | 11.50 | - | 4.42 | 6.92 |
| Operating Income | -235 | -307 | -189 | -173 | -117 | -87.37 | -55.02 | -42.44 | -61.72 | -8.09 |
| Net Income | -254 | -324 | -193 | -176 | -118 | -79.16 | -56.07 | -41.37 | -59.66 | -6.43 |
| Shares Outstanding | 84.56 | 76.89 | 66.58 | 61.89 | 58.63 | 43.10 | 34.98 | 26.55 | 23.35 | 13.25 |
| Earnings Per Share | -3.01 | -4.22 | -2.89 | -2.85 | -2.02 | -1.84 | -1.60 | -1.56 | -2.95 | -0.49 |
| Operating Cash Flow | -251 | -258 | -160 | -147 | -101 | -64.42 | -46.66 | -31.01 | -30.21 | -7.72 |
| Capital Expenditures | -42.27 | -13.09 | -3.00 | -4.20 | -3.45 | -5.34 | -0.82 | -0.29 | -0.98 | - |
| Free Cash Flow | -293 | -271 | -163 | -151 | -104 | -69.76 | -47.49 | -31.30 | -31.18 | -7.72 |
| Cash & Equivalents | 487 | 495 | 381 | 163 | 283 | 159 | 114 | 92.94 | 76.27 | 108 |
| Total Debt | 397 | 317 | 55.57 | 54.79 | 25.14 | 24.86 | 19.69 | 19.39 | 0.28 | 0.16 |
| Net Cash / Debt | 90.39 | 179 | 326 | 108 | 258 | 134 | 94.21 | 73.55 | 75.99 | 108 |
| Assets | 742 | 605 | 462 | 238 | 357 | 231 | 176 | 154 | 140 | 196 |
| Liabilities | 481 | 396 | 101 | 83.47 | 44.86 | 44.63 | 33.17 | 32.68 | 5.57 | 3.42 |
| Book Value | 262 | 208 | 361 | 154 | 312 | 186 | 143 | 121 | 134 | 193 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Insmed, Inc. |
| Country |
United States |
| Employees |
435 |
| CEO |
William H. Lewis |
Stock Information
| Ticker Symbol |
INSM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: INSM |
| IPO Date |
June 1, 2000 |
Description
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.